GEN Exclusives

More »

GEN News Highlights

More »
Jan 12, 2012

Amerigen and VIWA to Establish Chinese Generics Joint Venture

  • Amerigen Pharmaceuticals and VIWA Pharmaceutical inked an agreement through which they aim to set up a joint venture to develop and commercialize branded generic drugs for the Chinese market. The firms project that, once approved, resulting products will be manufactured at Amerigen’s Chinese SFDA- and U.S. FDA-approved plant in Suzhou, China. Marketing and sales would be undertaken by either a Chinese affiliate of VIWA, or a third party.

    “Combining Amerigen’s development capabilities, manufacturing assets, and access to products from Western markets with VIWA’s access to APIs and regulatory expertise in China should enable the joint venture to rapidly build up its product portfolio,” remarks Jack H. Ye, VIWA’s MD. “This in turn will help accelerate VIWA's strategic thrust into the commercialization of finished pharmaceutical products in China."

    VIWA Pharmaceutical is focused on the development and commercialization of finished pharmaceuticals for the Chinese and international markets. Generics firm Amerigen has a portfolio of generic drugs in development or filed with the FDA and SFDA. The firm specializes in challenging orally delivered products. 

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »